+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

DNases, Ligases, and RNA Polymerases Market Size, Share & Trends Analysis Report by Application (DNases-Biopharmaceutical Processing, Ligases- ligonucleotide Synthesis), Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 120 Pages
  • May 2024
  • Region: Global
  • Grand View Research
  • ID: 5681761
The global DNases, ligases, and RNA polymerases market size is expected to reach USD 1.62 billion by 2030. It is expected to expand at a CAGR of 10.63% from 2024 to 2030. Increasing research and development expenditure is one of the key factors fueling market growth. Furthermore, rising biopharmaceutical production along with a focus on DNA-related innovations is expected to positively impact the global DNases market growth over the forecast period.

For instance, in June 2020, Alphazyme and Codexis entered into a strategic partnership to provide novel enzymes for diagnostics and research. DNases have continued to garner a significant market share in recent years owing to factors such as an increase in the adoption of DNA enzymes related to pharmaceuticals, which are essential for the treatment of various chronic disorders and digestive diseases. In addition, developments in the biotechnology and pharmaceutical fields, such as the introduction of genetic and protein engineering, have helped in expanding applications of enzymes, which is expected to offer lucrative growth opportunities in the forecast period.

An increase in R&D investments to develop ligases as the target for therapeutic applications in cancer is estimated to drive the segment in the forecast period. In addition, strategic activities by major manufacturers will offer lucrative growth opportunities in the projected period. Other factors augmenting segment growth include advancements in healthcare, increasing demand for modernization in the field of medical academics and life sciences, growing investments by governments to develop genomic technologies, and a surge in the demand for oligonucleotide synthesis by private and public research firms.

The COVID-19 pandemic situation has offered lucrative opportunities for RNA polymerase applications. Currently, there are over 150 vaccines and therapeutics that either use mRNA in their production processes or are based on mRNA molecules, which are being assessed for the treatment of a wide range of indications. Many mRNA vaccines are approved for emergency use in many countries across the globe.

For instance, Moderna's mRNA-1273 and BioNTech/ Pfizer BNT-162 vaccines have been approved for use across various regions globally. Moreover, there are instances of huge capital investments for the development of mRNA vaccines. For instance, in June 2021, Sanofi declared an investment of around USD 452.12 annually for its mRNA vaccines development center.

DNases, Ligases, And RNA Polymerases Market Report Highlights

  • By DNAse application, the other applications segment dominated the market in 2023 due to a rise in DNA-based research, an increase in research funding, and reliable utility of DNase in applications
  • By ligase application, the other applications segment held the maximum share in 2023. Certain factors such as the rising use of ligases in gene therapies and growth in DNA sequencing are expected to play a major role in the segment growth during the forecast period
  • By RNA polymerases application, mRNA production dominated the market in 2023 due to increasing demand for mRNA-based vaccines for COVID-19 and research activities. For instance, Moderna is set to expand its mRNA vaccine pipeline with three new development programs. The programs will target the varicella-zoster virus (VSV), herpes simplex virus (HSV), and a novel checkpoint cancer vaccine
  • North America dominated the global market in 2023 owing to increasing demand for gene therapy, rise in the number of genetic disorders and cancer, the presence of research institutes, rising research funding for research on novel gene therapy, and rise in the demand for DNA-based vaccine production for COVID-19
  • Asia Pacific is expected to grow considerably in the future owing to the rising prevalence of genetic disorders, rising demand for gene therapy, and high population density

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. DNases Application
1.2.2. Ligases Application
1.2.3. RNA Polymerases Application
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis (Model 1)
1.7.2. Approach 1: Commodity Flow Approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. DNases, Ligases, and RNA Polymerases Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary Market Outlook.
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing Academic and Industrial Interest in MRNA Technology
3.2.1.2. Advancements in Biotechnology and Molecular Biology
3.2.1.3. Increasing Demand for Gene Therapy
3.2.2. Market Restraint Analysis
3.2.2.1. Regulatory Challenges Related to DNases, Ligases, and RNA Polymerases
3.3. DNases, Ligases, and RNA Polymerases Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. DNases, Ligases, and RNA Polymerases Market: DNases Application Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global DNases, Ligases, and RNA Polymerases Market DNases Application Movement Analysis
4.3. Global DNases, Ligases, and RNA Polymerases Market Size & Trend Analysis, by DNases Application, 2018 to 2030 (USD Million)
4.4. Biopharmaceutical Processing
4.4.1. Biopharmaceutical Processing Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.5. Other Applications
4.5.1. Other Applications Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 5. DNases, Ligases, and RNA Polymerases Market: Ligases Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global DNases, Ligases, and RNA Polymerases Market Ligases Application Movement Analysis
5.3. Global DNases, Ligases, and RNA Polymerases Market Size & Trend Analysis, by Ligases Application, 2018 to 2030 (USD Million)
5.4. Oligonucleotide Sysnthesis
5.4.1. Oligonucleotide Synthesis Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.5. Other Applications
5.5.1. Other Applications Methylation Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 6. DNases, Ligases, and RNA Polymerases Market: RNA Polymerases Application Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global DNases, Ligases, and RNA Polymerases Market RNA Polymerases Application Movement Analysis
6.3. Global DNases, Ligases, and RNA Polymerases Market Size & Trend Analysis, by RNA Polymerases Application, 2018 to 2030 (USD Million)
6.4. MRNA Production
6.4.1. MRNA Production Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5. Other Applications
6.5.1. Other Applications Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 7. DNases, Ligases, and RNA Polymerases Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. U.S.
7.4.1.1. Key Country Dynamics
7.4.1.2. Regulatory Framework
7.4.1.3. Competitive Scenario
7.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.4.2. Canada
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework
7.4.2.3. Competitive Scenario
7.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5. Europe
7.5.1. UK
7.5.1.1. Key Country Dynamics
7.5.1.2. Regulatory Framework
7.5.1.3. Competitive Scenario
7.5.1.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.2. Germany
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework
7.5.2.3. Competitive Scenario
7.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.3. France
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework
7.5.3.3. Competitive Scenario
7.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.4. Italy
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework
7.5.4.3. Competitive Scenario
7.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.5. Spain
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework
7.5.5.3. Competitive Scenario
7.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.6. Norway
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework
7.5.6.3. Competitive Scenario
7.5.6.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.7. Sweden
7.5.7.1. Key Country Dynamics
7.5.7.2. Regulatory Framework
7.5.7.3. Competitive Scenario
7.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.8. Denmark
7.5.8.1. Key Country Dynamics
7.5.8.2. Regulatory Framework
7.5.8.3. Competitive Scenario
7.5.8.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6. Asia-Pacific
7.6.1. Japan
7.6.1.1. Key Country Dynamics
7.6.1.2. Regulatory Framework
7.6.1.3. Competitive Scenario
7.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6.2. China
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework
7.6.2.3. Competitive Scenario
7.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6.3. India
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework
7.6.3.3. Competitive Scenario
7.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6.4. Australia
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework
7.6.4.3. Competitive Scenario
7.6.4.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6.5. South Korea
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework
7.6.5.3. Competitive Scenario
7.6.5.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6.6. Thailand
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework
7.6.6.3. Competitive Scenario
7.6.6.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.7. Latin America
7.7.1. Brazil
7.7.1.1. Key Country Dynamics
7.7.1.2. Regulatory Framework
7.7.1.3. Competitive Scenario
7.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.7.2. Mexico
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework
7.7.2.3. Competitive Scenario
7.7.2.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework
7.7.3.3. Competitive Scenario
7.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.8. MEA
7.8.1. South Africa
7.8.1.1. Key Country Dynamics
7.8.1.2. Regulatory Framework
7.8.1.3. Competitive Scenario
7.8.1.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.8.2. Saudi Arabia
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework
7.8.2.3. Competitive Scenario
7.8.2.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.8.3. UAE
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework
7.8.3.3. Competitive Scenario
7.8.3.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.8.4. Kuwait
7.8.4.1. Key Country Dynamics
7.8.4.2. Regulatory Framework
7.8.4.3. Competitive Scenario
7.8.4.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company/Competition Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2023
8.4. Company Profiles/Listing
8.4.1. Thermo Fisher Scientific, Inc.
8.4.1.1. Company Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Merck KGaA
8.4.2.1. Company Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Agilent Technologies, Inc.
8.4.3.1. Company Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Promega Corporation
8.4.4.1. Company Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. New England Biolabs
8.4.5.1. Company Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. RayBiotech, Inc.
8.4.6.1. Company Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. BioVision, Inc.
8.4.7.1. Company Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. ABclonal, Inc.
8.4.8.1. Company Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. QIAGEN N.V.
8.4.9.1. Company Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Takara Bio, Inc.
8.4.10.1. Company Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
8.4.11. Abnova Corporation.
8.4.11.1. Company Overview
8.4.11.2. Financial Performance
8.4.11.3. Product Benchmarking
8.4.11.4. Strategic Initiatives
8.4.12. Calzyme
8.4.12.1. Company Overview
8.4.12.2. Financial Performance
8.4.12.3. Product Benchmarking
8.4.12.4. Strategic Initiatives
8.4.13. ArcticZymes Technologies
8.4.13.1. Company Overview
8.4.13.2. Financial Performance
8.4.13.3. Product Benchmarking
8.4.13.4. Strategic Initiatives
8.4.14. Worthington Biochemical Corporation
8.4.14.1. Company Overview
8.4.14.2. Financial Performance
8.4.14.3. Product Benchmarking
8.4.14.4. Strategic Initiatives
8.4.15. MBL International
8.4.15.1. Company Overview
8.4.15.2. Financial Performance
8.4.15.3. Product Benchmarking
8.4.15.4. Strategic Initiatives
8.4.16. MyBioSource
8.4.16.1. Company Overview
8.4.16.2. Financial Performance
8.4.16.3. Product Benchmarking
8.4.16.4. Strategic Initiatives
8.4.17. BPS Bioscience Inc.
8.4.17.1. Company Overview
8.4.17.2. Financial Performance
8.4.17.3. Product Benchmarking
8.4.17.4. Strategic Initiatives
8.4.18. Sino Biological
8.4.18.1. Company Overview
8.4.18.2. Financial Performance
8.4.18.3. Product Benchmarking
8.4.18.4. Strategic Initiatives
8.4.19. Novus Biologicals
8.4.19.1. Company Overview
8.4.19.2. Financial Performance
8.4.19.3. Product Benchmarking
8.4.19.4. Strategic Initiatives
List of Tables
Table 1 List of Abbreviation
Table 2 Key Funding for MRNA R&d in 2020-2022
Table 3 Clinical Development of MRNA Vaccine Candidates Against COVID-19
Table 4 Global DNases, Ligases, and RNA Polymerases Market, by Region, 2018-2030 (USD Million)
Table 5 Global DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 6 Global DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 7 Global DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 8 Global DNases, Ligases, and RNA Polymerases Market, 2018-2030 (USD Million)
Table 9 North America DNases, Ligases, and RNA Polymerases Market, by Country, 2018-2030 (USD Million)
Table 10 North America DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 11 North America DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 12 North America DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 13 U.S. DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 14 U.S. DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 15 U.S. DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 16 Canada DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 17 Canada DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 18 Canada DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 19 Europe DNases, Ligases, and RNA Polymerases Market, by Country, 2018-2030 (USD Million)
Table 20 Europe DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 21 Europe DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 22 Europe DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 23 Germany DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 24 Germany DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 25 Germany DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 26 UK DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 27 UK DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 28 UK DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 29 France DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 30 France DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 31 France DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 32 Italy DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 33 Italy DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 34 Italy DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 35 Spain DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 36 Spain DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 37 Spain DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 38 Denmark DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 39 Denmark DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 40 Denmark DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 41 Sweden DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 42 Sweden DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 43 Sweden DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 44 Norway DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 45 Norway DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 46 Norway DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 47 Asia-Pacific DNases, Ligases, and RNA Polymerases Market, by Country, 2018-2030 (USD Million)
Table 48 Asia-Pacific DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 49 Asia-Pacific DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 50 Asia-Pacific DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 51 China DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 52 China DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 53 China DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 54 Japan DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 55 Japan DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 56 Japan DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 57 India DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 58 India DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 59 India DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 60 South Korea DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 61 South Korea DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 62 South Korea DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 63 Australia DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 64 Australia DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 65 Australia DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 66 Thailand DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 67 Thailand DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 68 Thailand DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 69 Latin America DNases, Ligases, and RNA Polymerases Market, by Country, 2018-2030 (USD Million)
Table 70 Latin America DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 71 Latin America DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 72 Latin America DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 73 Brazil DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 74 Brazil DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 75 Brazil DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 76 Mexico DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 77 Mexico DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 78 Mexico DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 79 Argentina DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 80 Argentina DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 81 Argentina DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 82 MEA DNases, Ligases, and RNA Polymerases Market, by Country, 2018-2030 (USD Million)
Table 83 MEA DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 84 MEA DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 85 MEA DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 86 South Africa DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 87 South Africa DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 88 South Africa DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 89 Saudi Arabia DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 90 Saudi Arabia DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 91 Saudi Arabia DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 92 UAE DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 93 UAE DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 94 UAE DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 95 Kuwait DNases, Ligases, and RNA Polymerases Market, by DNases Application, 2018-2030 (USD Million)
Table 96 Kuwait DNases, Ligases, and RNA Polymerases Market, by Ligases Application, 2018-2030 (USD Million)
Table 97 Kuwait DNases, Ligases, and RNA Polymerases Market, by RNA Polymerases Application, 2018-2030 (USD Million)
Table 98 Key Companies Undergoing Expansions
Table 99 Key Companies Undergoing Acquisitions
Table 100 Key Companies Undergoing Expansions
Table 101 Key Companies Undertaking New Launch
Table 102 Key Companies Undertaking New Launch
List of Figures
Figure 1 DNases, Ligases, and RNA Polymerases Market Segmentation
Figure 2 Data Analysis Models
Figure 3 Market Formulation and Validation
Figure 4 Data Validation & Publishing
Figure 5 Market Research Process
Figure 6 Information Procurement
Figure 7 Primary Research
Figure 8 Value-chain-based Sizing & Forecasting
Figure 9 QFD Modelling for Market Share Assessment
Figure 10 Market Formulation & Validation
Figure 11 Commodity Flow Analysis
Figure 12 Market Snapshot
Figure 13 Segment Snapshot - 1
Figure 14 Segment Snapshot - 2
Figure 15 Competitive Landscape Snapshot
Figure 16 Biotechnology Market Value, 2023 (USD Billion)
Figure 17 Market Trends & Outlook
Figure 18 Gene Therapies in Clinical Trials in 2022 Globally
Figure 19 PESTEL Analysis
Figure 20 Porter’s Five Forces Analysis
Figure 21 DNases Market: Application Outlook & Key Takeaways
Figure 22 DNases Market: Application Movement Analysis
Figure 23 Global Biopharmaceutical Processing Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 24 Global Other Applications Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 25 Ligases Market: Application Outlook & Key Takeaways
Figure 26 Ligases Market: Application Movement Analysis
Figure 27 Global Oligonucleotide Synthesis Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 28 Global Other Applications Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 29 RNA Polymerases Market: Application Outlook & Key Takeaways
Figure 30 RNA Polymerases Market: Application Movement Analysis
Figure 31 Global MRNA Production Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 32 Global Other Applications Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 33 Regional Marketplace Outlook, 2023 & 2030, (USD Million)
Figure 34 Regional Marketplace: Key Takeaways
Figure 35 North America DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 36 Key Country Dynamics
Figure 37 U.S. DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 38 Key Country Dynamics
Figure 39 Canada DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 40 Europe DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 41 Key Country Dynamics
Figure 42 Germany DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 43 Key Country Dynamics
Figure 44 UK DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 45 Key Country Dynamics
Figure 46 France DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 47 Key Country Dynamics
Figure 48 Italy DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 49 Key Country Dynamics
Figure 50 Spain DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 51 Key Country Dynamics
Figure 52 Denmark DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 53 Key Country Dynamics
Figure 54 Norway DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 55 Key Country Dynamics
Figure 56 Sweden DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 57 Asia-Pacific DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 58 Key Country Dynamics
Figure 59 Japan DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 60 Key Country Dynamics
Figure 61 China DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 62 Key Country Dynamics
Figure 63 India DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 64 Key Country Dynamics
Figure 65 Australia DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 66 Key Country Dynamics
Figure 67 Thailand DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 68 Key Country Dynamics
Figure 69 South Korea DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 70 Key Country Dynamics
Figure 71 Singapore DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 72 Latin America DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 73 Key Country Dynamics
Figure 74 Brazil DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 75 Key Country Dynamics
Figure 76 Mexico DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 77 Key Country Dynamics
Figure 78 Argentina DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 79 MEA DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 80 Key Country Dynamics
Figure 81 South Africa DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 82 Key Country Dynamics
Figure 83 Saudi Arabia DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 84 Key Country Dynamics
Figure 85 UAE DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 86 Key Country Dynamics
Figure 87 Kuwait DNases, Ligases, and RNA Polymerases Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 88 Market Participant Categorization
Figure 89 Global DNases, Ligases, and RNA Polymerases Market Heat Map Analysis, 2023
Figure 90 Strategic Framework

Companies Mentioned

  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Agilent Technologies, Inc.
  • Promega Corporation
  • New England Biolabs
  • RayBiotech, Inc.
  • BioVision, Inc.
  • ABclonal, Inc.
  • QIAGEN N.V.
  • Takara Bio, Inc.
  • Abnova Corporation.
  • Calzyme
  • ArcticZymes Technologies
  • Worthington Biochemical Corporation
  • MBL International
  • MyBioSource
  • BPS Bioscience Inc.
  • Sino Biological
  • Novus Biologicals

Methodology

Loading
LOADING...

Table Information